Mitral Valve Regurgitation Clinical Trial
Official title:
Understanding the Metabolic and Functional Derangement of Primary Mitral Regurgitation: a Feasibility Study Using C-11 Acetate Cardiac PET-MRI
The aim of this pilot imaging study is to investigate the underlying changes in myocardial oxidative metabolism, myocardial inflammation and alterations in extracellular volume in patients with chronic compensated moderate-severe primary mitral regurgitation (PMR). The PET tracer [11C] acetate will be used to image and quantify myocardial oxygen consumption (MVO2) in hearts of the study participants. Cardiac magnetic resonance imaging (CMR) using a gadolinium-based contrast agent (GBCA) will be performed to assess for and quantify expansion of myocardial extracellular volume (ECV) and myocardial inflammation. We will enroll a total of 12 participants, nine of whom will be patients with chronic, compensated asymptomatic moderate-severe PMR evaluated at the UAB Cardiovascular Disease and Structural Valve Clinic and three normal control subjects.
Status | Not yet recruiting |
Enrollment | 12 |
Est. completion date | August 31, 2028 |
Est. primary completion date | August 31, 2028 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - At least 18 years of age. - Patients with chronic, asymptomatic, compensated PMR evaluated in the UAB Structural Valve Clinic OR Normal controls identified from a normal aged matched population. - Negative urine or serum ß-human chorionic gonadotropin (hcg) test within 48 hours of [11C] acetate administration in women of childbearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing. Exclusion Criteria: - Inability to provide informed consent - Pregnancy - Inability to lie still for the imaging study - Weight exceeding the weight limit of the PET imaging table (500 pounds) - Comorbidities including any of the following: history of coronary artery disease, prior coronary revascularization, prior myocardial infarction, prior open sternotomy, history of congestive heart failure, history of non-ischemic cardiomyopathy including dilated, restrictive, hypertrophic, amyloid heart disease, cardiac sarcoidosis, history of hypertension, diabetes mellitus, chronic kidney disease with a glomerular filtration rate (GFR) less than 60 ml/min/1.73 m2 , history of other valvular heart disease defined as mitral stenosis, aortic stenosis, more than mild aortic regurgitation, more than mild tricuspid regurgitation, history of more than mild pulmonary hypertension and history of cancer with exposure to chemotherapy or radiotherapy. - Contraindication for gadolinium-based contrast agent, ProHance (gadoteridol) - Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos) |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama at Birmingham | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantitatively correlate metabolic findings from the PET component with quantitative T1 and T2 parametric mapping from the cardiac MR component of the hybrid PET-MR study. | Parametric analysis of T1 and T2 mapping will be performed using dedicated software (Qmap, Medis). | 0-48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02520310 -
AVJ-514 Japan Trial
|
N/A | |
Not yet recruiting |
NCT06465745 -
AltaValve Pivotal Trial
|
N/A | |
Completed |
NCT02355418 -
The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
|
||
Recruiting |
NCT04577248 -
The Prospecive OBSERVational Munich Interventional MITRAl-Valve Registry
|
||
Recruiting |
NCT03242642 -
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
|
N/A | |
Recruiting |
NCT02961647 -
Hemodynamic Stress Test in Severe Mitral Regurgitation (HEMI)
|
N/A | |
Active, not recruiting |
NCT02302872 -
Treatment of Heart Failure and Associated Functional Mitral Valve Regurgitation
|
N/A | |
Completed |
NCT01777815 -
Safety and Performance Study of the NeoChord Device
|
N/A | |
Withdrawn |
NCT00428103 -
Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy
|
N/A | |
Completed |
NCT04351984 -
Transcatheter Mitral Valvuloplasty Pilot Study
|
||
Withdrawn |
NCT02722551 -
CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02321514 -
Expanded Clinical Study of the Tendyne Mitral Valve System
|
N/A | |
Recruiting |
NCT02245763 -
STS/ACC TVT Registry Mitral Module
|
||
Active, not recruiting |
NCT01740583 -
Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation
|
N/A | |
Completed |
NCT00800046 -
A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study
|
N/A | |
Completed |
NCT00415701 -
Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery
|
Phase 4 | |
Recruiting |
NCT03908983 -
OPtimisation of Surgical Repair for Treating Insufficiency of the MItral Valve - Safety and Effectiveness Evaluation
|
N/A | |
Active, not recruiting |
NCT04818502 -
Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation
|
||
Terminated |
NCT03285724 -
Safety and Performance Study of the Harpoon Mitral Valve Repair System
|
N/A | |
Recruiting |
NCT04195984 -
Mi-thos® Transcatheter Mitral Valve Replacement Study
|
N/A |